恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 02-12 16:08:09

70.600

+0.500

+0.71%

最高72.000	最低70.000	成交量256.93万
今开70.000	昨收70.100	日振幅2.85%
总市值4,686亿	流通市值182.15亿	总股本66.37亿
成交额1.82亿	换手率1.00%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":70.6,"timestamp":1770883689004,"preClose":70.1,"halted":0,"volume":2569260,"delay":0,"changeRate":0.007132667617689016,"floatShares":258000000,"shares":6637000000,"eps":1.1331441659045254,"marketStatus":"未开盘","change":0.5,"latestTime":"02-12 16:08:09","open":70,"high":72,"low":70,"amount":181969075,"amplitude":0.028531,"askPrice":70.75,"askSize":8800,"bidPrice":70.6,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":1.3146829264357576,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770946200000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":70.1,"openAndCloseTimeList":[[1770859800000,1770868800000],[1770872400000,1770883200000]],"volumeRatio":1.148272933635616,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":58.74,"timestamp":1770879600000,"preClose":58.9,"halted":0,"volume":34868900,"delay":0,"premium":"+6.07"}},"requestUrl":"/m/hq/s/01276/wiki","defaultTab":"wiki","newsList":[{"id":"2610919168","title":"国联民生证券：小核酸重构减肥逻辑 INHBE与ALK7靶点初步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2610919168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610919168?lang=zh_cn&edition=full","pubTime":"2026-02-12 14:27","pubTimestamp":1770877647,"startTime":"0","endTime":"0","summary":"小核酸减肥靶点主要有INHBE靶点、ARO-ALK7靶点以及靶向肌肉的GeneD靶点三个，中国药企在小核酸减肥适应症的布局速度几乎与海外药企同步。国联民生证券主要观点如下：Arrowhead公布两款小核酸药物的初步减肥疗效良好Arrowhead公司公布了两个靶点INHBE和ALK7的小核酸药物的减肥效果，展现出良好的初步疗效：ARO-INHBE精准减脂：脂肪平均减少9.9%，肝脏脂肪减少幅度高达38.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","01177","BK1589","LU0359201612.USD","BK1515","BK1191","IE00BZ08YR35.GBP","00867","LU0359201885.HKD","IE00BVYPNP33.GBP","BK1564","BK1147","01276","IE00BYV24P56.USD","LU2543165471.USD","IE00BGHQDM52.EUR","LU0359202008.SGD","SG9999015952.SGD","601456","SG9999015978.USD","SG9999004220.SGD","BK1593","LU2488822045.USD","IE00BZ08YS42.EUR","BK0276","IE00BVYPNQ40.USD","HK0000165453.HKD","01456","SG9999015945.SGD","LU1023057109.AUD","161027","IE00BMCWC346.EUR","BK1521","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2610993166","title":"恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993166","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610993166?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:37","pubTimestamp":1770809832,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648077695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU0405327148.USD","BK0188","LU2097828474.EUR","LU0359201612.USD","BK1191","BK0012","600276","BK0196","LU2328871848.SGD","LU1997245094.SGD","159992","LU1580142542.USD","LU1997244956.HKD","LU1655091616.SGD","LU1969619763.USD","LU0359201885.HKD","LU1023057109.AUD","LU0405327494.USD","LU2289578879.USD","01276","LU1820825898.SGD","LU1255011170.USD","LU2488822045.USD","LU1997245177.USD","LU1781817850.SGD","LU2097828631.EUR","LU1064131003.USD","BK0060","LU1064130708.USD","LU2580892789.USD","BK0183","LU1146622755.USD","LU2097828714.EUR","LU1328615791.USD","BK1574","LU2495084118.USD","BK1161","LU2097828805.USD","LU2148510915.USD","06978","LU2097828557.USD","BK0028","BK0239","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0},{"id":"2610544938","title":"恒瑞医药：公司2025年利润分配方案尚未披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2610544938","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610544938?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:35","pubTimestamp":1770802536,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年利润分配方案尚未披露，敬请关注公司后续于交易所网站上发布的相关公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113647979496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU1064130708.USD","01276","LU1146622755.USD","LU2328871848.SGD","LU2488822045.USD","LU2580892789.USD","BK0028","LU2097828714.EUR","BK0060","LU2580892862.HKD","LU0359201612.USD","BK0183","BK0239","LU1969619763.USD","LU2097828557.USD","BK0196","LU0359202008.SGD","LU1781817850.SGD","LU1997245177.USD","LU1023057109.AUD","BK1191","LU0405327494.USD","BK0012","LU0359201885.HKD","LU2097828631.EUR","LU2495084118.USD","600276","BK0188","LU1580142542.USD","LU1655091616.SGD","LU1328615791.USD","LU1997245094.SGD","LU1820825898.SGD","LU2097828805.USD","LU2148510915.USD","LU2289578879.USD","LU2097828474.EUR","LU0405327148.USD","LU1997244956.HKD","LU2543165471.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2610893956","title":"口服GLP-1成热门赛道！华东医药、信达生物、德睿智药、恒瑞医药等加速竞逐","url":"https://stock-news.laohu8.com/highlight/detail?id=2610893956","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610893956?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:52","pubTimestamp":1770796351,"startTime":"0","endTime":"0","summary":"在国产口服GLP-1管线中，华东医药、信达生物、德睿智药、恒瑞医药等企业的产品进度较快。通过高效特异性靶向激活GLP-1R，引发级联信号转导，从而延缓胃排空、抑制食欲、促进胰岛素分泌，达到治疗肥胖、2型糖尿病等胰岛素相关代谢疾病的目的。同时，已有多款国产GLP-1药物达成海外授权，彰显了国产创新药的国际认可度。随着临床研究的持续推进，国产口服GLP-1药物有望惠及更多代谢性疾病患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211155455a6edf1a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211155455a6edf1a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1583","LU0359201612.USD","BK1191","HK0000165453.HKD","LU2097828631.EUR","01801","LU2328871848.SGD","LU2488822045.USD","LU2097828805.USD","BK1161","LU2097828557.USD","LU2543165471.USD","LU0359202008.SGD","LU2097828714.EUR","01276","LU1969619763.USD","BK1589","LU0359201885.HKD","LU2242644610.SGD","LU2097828474.EUR","LU0455707207.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2610647773","title":"恒瑞医药(01276)：注射用瑞康曲妥珠单抗上市许可申请获受理并纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610647773?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:36","pubTimestamp":1770726994,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。研究结果显示，与标准治疗方案相比，瑞康曲妥珠单抗能显著延长HER2 阳性晚期结直肠癌患者的PFS，降低疾病进展或死亡风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1997245094.SGD","LU1969619763.USD","LU2289578879.USD","LU2148510915.USD","LU2580892789.USD","BK1191","LU0359201612.USD","LU2580892862.HKD","LU2097828805.USD","LU1580142542.USD","LU1328615791.USD","LU2097828474.EUR","LU1997244956.HKD","LU1997245177.USD","LU2097828557.USD","BK0028","LU1146622755.USD","BK0012","BK0188","LU0359202008.SGD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","LU1655091616.SGD","LU1064131003.USD","BK0196","LU1781817850.SGD","LU2097828631.EUR","01276","600276","BK0183","LU2328871848.SGD","LU1023057109.AUD","LU1255011170.USD","LU2543165471.USD","BK0060","LU1820825898.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2610969486","title":"创新药概念震荡反弹 高增长潜力概念股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","media":"腾讯自选股综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:17","pubTimestamp":1770693474,"startTime":"0","endTime":"0","summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","01548","00013","06185","00867","02228","03692","01801","02269","06160","01877","02196","BK1574","00512","01952","01093","06978","BK1515","01513","01177","BK1583","BK1161","02096"],"gpt_icon":0},{"id":"2610958611","title":"恒瑞医药创新止吐药拓展新适应症，为中度致吐化疗患者带来新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958611","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610958611?lang=zh_cn&edition=full","pubTime":"2026-02-10 07:04","pubTimestamp":1770678293,"startTime":"0","endTime":"0","summary":"1月30日，恒瑞医药宣布其自主研发的注射用磷罗拉匹坦帕洛诺司琼新适应症上市许可申请获正式受理。该药拟定用于预防成年患者因中度致吐性抗肿瘤药物引起的急性和迟发性恶心呕吐。此次新适应症的申请，基于一项代号为HR20013-302的多中心、随机、双盲、阳性对照的Ⅲ期临床试验。这意味着，如果恒瑞医药的注射用磷罗拉匹坦帕洛诺司琼新适应症获批，将成为国内首个该类药物注射剂型，填补市场空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021007104397a58866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021007104397a58866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","BK1191","LU0359201885.HKD","01276","LU0359202008.SGD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2610663752","title":"资本市场坚定看好“上海药”！这张“成绩单”见证申城创新实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2610663752","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610663752?lang=zh_cn&edition=full","pubTime":"2026-02-10 04:02","pubTimestamp":1770667361,"startTime":"0","endTime":"0","summary":"图为上海一家生物医药企业的研发中心内景。新近发布的一张重量级年度榜单，让人在“十四五”收官、“十五五”开局之际，见证了上海生物医药产业的创新实力：2025年，无论是创新药械获批量、产业国际化发展业绩，还是上市企业总体表现，上海都位居国内前列，涌现出一批行业领头羊。特别是按研发管线数排序，全国前十中有八家企业出自上海。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602103645823262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU2097828805.USD","01801","LU0455707207.USD","LU1023057109.AUD","LU2097828474.EUR","BK1583","LU0359202008.SGD","LU2543165471.USD","BK4588","01276","LU2328871848.SGD","BK1161","LABU","LU1969619763.USD","LU0359201885.HKD","BK4585","LU2242644610.SGD","HK0000165453.HKD","LU2097828557.USD","LU2488822045.USD","BK1191","BK1589","LU0359201612.USD","LU2097828714.EUR","LU0502904849.HKD"],"gpt_icon":0},{"id":"2610368636","title":"每日卖空追踪 | 恒瑞医药 02月09日卖空量成交12.04万股，卖空比例为5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610368636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610368636?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625820,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间02月09日，涨2.07%，卖空量成交12.04万股，较上一交易日减少76.76%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163622a48e5a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163622a48e5a53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0},{"id":"2610636858","title":"恒瑞医药HR091506片上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636858","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636858?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:21","pubTimestamp":1770625260,"startTime":"0","endTime":"0","summary":"恒瑞医药自主研发的化学药品2类新药HR091506片上市许可申请获国家药监局受理，用于痛风患者高尿酸血症长期治疗。研究结果显示，HR091506片在主要终点上显著优于对照组，且长期治疗安全性、耐受性良好。痛风与高尿酸血症直接相关，可并发肾脏病变及多种代谢性疾病。HR091506片是采用胃滞留制剂技术自主研发的非布司他口服缓释片剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209162249a48e499c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209162249a48e499c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","BK1191","LU1023057109.AUD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2610843176","title":"恒瑞医药再添新进展，国产痛风药物迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2610843176","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610843176?lang=zh_cn&edition=full","pubTime":"2026-02-09 11:39","pubTimestamp":1770608397,"startTime":"0","endTime":"0","summary":"资料显示，恒瑞医药的HR091506片，采用胃滞留制剂技术研发，具有脉冲释放特性。此外，恒瑞医药在痛风药物领域，1类新药SHR4640片的药品上市许可申请已经于2025年初获国家药监局受理，适应症为适用于原发性痛风伴高尿酸血症的长期治疗。它标志着中国痛风治疗将进入新阶段，为改善患者长期预后带来希望。未来随着更多药物获批上市，相关患者有望迎来更多新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209114236a6e44a30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209114236a6e44a30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201612.USD","LU1023057109.AUD","BK1191","LU0359201885.HKD","LU2543165471.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2610684300","title":"超百家公司业绩预喜！掘金创新药，机会如何展望？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610684300","media":"浙商证券融资融券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610684300?lang=zh_cn&edition=full","pubTime":"2026-02-09 11:11","pubTimestamp":1770606688,"startTime":"0","endTime":"0","summary":"创新药迎催化：截至1月31日，共有283只医药股披露了2025年业绩预告。按预告归母净利润上限看，共有160只个股归母净利润同比增长，部分公司业绩超预期，板块迎来业绩催化。港股IPO与再融资同步修复，2025年募资超800亿港元，创新药企业融资通道持续畅通，为研发投入与全球化布局提供充足资金。同时，FDA推动连续性试验与AI应用，中美监管均向“效率优先”转型，缩短新药上市周期，为创新药快速兑现商业化价值提供制度保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209113636a48d50e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209113636a48d50e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","LU0359201612.USD","LU0359201885.HKD","LU1023057109.AUD","01276","BK1191","LU0359202008.SGD","02359","03347","06160","LU2543165471.USD","BK1161"],"gpt_icon":0},{"id":"2610663507","title":"医药生物行业跟踪周报：分子胶海外风起 国内管线蓄势破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2610663507","media":"东吴证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610663507?lang=zh_cn&edition=full","pubTime":"2026-02-09 00:00","pubTimestamp":1770566400,"startTime":"0","endTime":"0","summary":"分子胶海外风起，已经诞生RVMD、GLU、KYMR 等多个大牛股，并且已经诞生多个重大BD，国内企业已有较多布局，但是关注度较低，存在较大认知差。奥赛康BD 引进ANL pan-RAS 分子胶的中国权益，预计26Q1 开展1 期临床；达歌生物已经与武田、默沙东建立合作，拥有两款FIC 分子胶，DAC 亦有布局。我们认为，分子胶有望在肿瘤及自身免疫病等广阔市场中催生出新一代重磅炸弹级药物，建议重点关注国内布局企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209170638a48e7ce6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209170638a48e7ce6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","09606","BK1191","LU0359201885.HKD","LU2543165471.USD","LU0359201612.USD","02228","LU0359202008.SGD","01276"],"gpt_icon":0},{"id":"2610011635","title":"医药行业周报：本周申万医药生物指数上涨0.14% 关注中药高质量发展方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2610011635","media":"申万宏源研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610011635?lang=zh_cn&edition=full","pubTime":"2026-02-09 00:00","pubTimestamp":1770566400,"startTime":"0","endTime":"0","summary":"市场表现：本周申万医药生物指数上涨0.1%，同期上证指数下跌1.27%，万得全A下跌1.8%。本周医药生物指数在31 个申万一级子行业中表现排名第15 。工业和信息化部等八部门联合印发《中药工业高质量发展实施方案》。康众医疗增资7000 万元参股人工智能医疗科技企业脉得智能，本次增资完成后，公司将持有脉得智能7.37%的股权。济川药业获得普祺医药JAKi 鼻喷雾剂商业化授权，交易总额达1 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209165636a6e56572&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209165636a6e56572&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201885.HKD","LU2543165471.USD","LU1023057109.AUD","LU0359202008.SGD","01276","LU0359201612.USD","03347"],"gpt_icon":0},{"id":"2610845886","title":"速递｜恒瑞减重资产走向全球：Kaliera携三款GLP-1冲刺国际肥胖药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2610845886","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610845886?lang=zh_cn&edition=full","pubTime":"2026-02-08 22:19","pubTimestamp":1770560350,"startTime":"0","endTime":"0","summary":"Kaliera成立于2024年10月，定位极为清晰，即将肥胖视为一种需要长期、系统治疗的慢性疾病，而非单纯的生活方式问题。其中，HRS-9531是Kaliera当前最核心、也是最具全球竞争潜力的资产。基于中国临床数据，Kaliera已同步启动HRS-9531的全球三期临床项目KaiNETIC计划。从时间表看，Kaliera的国际化推进节奏清晰且紧凑。在全球减重药物竞争日趋激烈、监管持续收紧的背景下，Kaliera的出现，标志着中国创新药企业正在从“参与者”向“规则竞争者”转变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020910074995405b97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020910074995405b97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","BK1191","LU1023057109.AUD","01276","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":1},{"id":"2609420569","title":"恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609420569","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609420569?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:47","pubTimestamp":1770371265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例，居恶性肿瘤发病第12位;死亡病例为467,005例，居恶性肿瘤发病第6位，约占全球癌症死亡人数的5%。HRS-4642注射液是公司自主研发的KRAS G12D抑制剂，为脂质体剂型。经查询，目前国内外尚无同类药物获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","600276","LU1146622755.USD","BK0196","BK0012","LU2097828631.EUR","01276","LU0359201612.USD","BK0188","LU1328615791.USD","LU2328871848.SGD","LU2097828714.EUR","LU0359202008.SGD","LU1655091616.SGD","LU1023057109.AUD","LU2580892862.HKD","BK0239","LU2097828557.USD","BK1191","LU1580142542.USD","LU1820825898.SGD","BK0060","LU1064131003.USD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU2097828805.USD","LU2488822045.USD","LU2543165471.USD","LU1781817850.SGD","LU2097828474.EUR","LU1997244956.HKD","LU2580892789.USD","LU2289578879.USD","LU0405327148.USD","LU1255011170.USD","LU1997245094.SGD","BK0028","LU1064130708.USD","LU0359201885.HKD","LU1997245177.USD","BK0183"],"gpt_icon":0},{"id":"2609161785","title":"每日卖空追踪 | 恒瑞医药 02月06日卖空量成交24.08万股，卖空比例为12.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609161785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609161785?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366621,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间02月06日，跌1.31%，卖空量成交24.08万股，较上一交易日减少55.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163256a483cd08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163256a483cd08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU0359202008.SGD","01276","LU1023057109.AUD","LU0359201612.USD","LU0359201885.HKD","BK1191"],"gpt_icon":0},{"id":"2609464516","title":"恒瑞医药，第三次闯关FDA！","url":"https://stock-news.laohu8.com/highlight/detail?id=2609464516","media":"药融圈","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609464516?lang=zh_cn&edition=full","pubTime":"2026-02-06 09:04","pubTimestamp":1770339866,"startTime":"0","endTime":"0","summary":"2月2日，恒瑞医药发布公告，宣布PD-1抗体卡瑞利珠单抗重新递交的上市申请获得FDA受理，联合阿帕替尼用于不可切除或转移性肝细胞癌患者一线治疗，PDUFA日期为2026年7月23日。值得注意的是，此次已经是恒瑞“双艾”组合第三次征战FDA了。虽然“双艾”组合此前两次曾被FDA拒绝批准，但主要还是生产问题，并不涉及疗效问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206092043a4823de6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206092043a4823de6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","LU0359202008.SGD","01276","LU1023057109.AUD","LU0359201612.USD","LU0359201885.HKD","BK1191"],"gpt_icon":0},{"id":"2609327389","title":"恒瑞医药子公司获批SHR-1894注射液临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2609327389","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609327389?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:53","pubTimestamp":1770281616,"startTime":"0","endTime":"0","summary":"2月5日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-1894注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物是公司自主研发的治疗用生物制品，预期可在特应性皮炎治疗中发挥保护皮肤屏障和抑制炎症的作用。目前国内外尚无同类药物获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642799628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","LU1655091616.SGD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU0405327494.USD","LU1328615791.USD","LU1997244956.HKD","LU2289578879.USD","LU0405327148.USD","LU1064131003.USD","BK1191","LU1064130708.USD","BK0060","LU1997245094.SGD","LU2543165471.USD","LU2097828714.EUR","BK0188","LU1781817850.SGD","LU0359201612.USD","LU0359201885.HKD","LU1580142542.USD","LU1997245177.USD","BK0196","LU1255011170.USD","LU2097828805.USD","BK0239","LU1146622755.USD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","BK0183","BK0028","LU1820825898.SGD","BK0012","LU2097828474.EUR","LU2328871848.SGD","01276","LU0359202008.SGD","600276"],"gpt_icon":0},{"id":"2609371946","title":"每日卖空追踪 | 恒瑞医药 02月05日卖空量成交24.74万股，卖空比例为11.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609371946","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609371946?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:30","pubTimestamp":1770280220,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间02月05日，涨2.7%，卖空量成交24.74万股，较上一交易日减少71.46%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163411a47f602d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205163411a47f602d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU2543165471.USD","LU1023057109.AUD","BK1191","LU0359201885.HKD","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.1029},{"period":"3month","weight":-0.014},{"period":"6month","weight":-0.1395},{"period":"1year","weight":0.6027},{"period":"ytd","weight":-0.0091}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0069},{"period":"3month","weight":-0.0015},{"period":"6month","weight":0.0697},{"period":"1year","weight":0.2367},{"period":"ytd","weight":0.0547}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}